Infection with the SARS-CoV-2 virus carries an elevated risk of thrombosis compared to
other viral respiratory infections. 1 In addition to “macrovascular” thrombotic complications …

Thrombosis in patients with coronavirus disease 2019 (Covid-19) is driven by complex
interactions between immune, complement, fibrinolytic, endothelial, and coagulation …

Among the distinguishing features of coronavirus disease-2019 (COVID-19) is a severely
increased risk for arterial and venous thrombotic complications. It was rapidly recognized …

Thrombosis is common in patients with coronavirus disease 2019 (COVID-19)-associated
moderate illness. A systematic review and meta-analysis reported venous thromboembolism …

There were initially three clear lines of evidence in support of an association between
thrombosis and coronavirus disease 2019 (COVID-19), as caused by SARS-CoV-2 (severe …

Background Thrombosis may contribute to morbidity and mortality in Covid-19. We
hypothesized that therapeutic anticoagulation would improve outcomes in critically ill …

Infection by the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), the cause
of COVID-19, has been associated with numerous other medical complications aside from …

Early in the COVID-19 pandemic, it became clear that coagulopathy leading to
macrovascular and microvascular thrombotic events was a considerable potential …

Thrombotic complications in COVID-19 are highest in the most sick patients, reflecting
inflammatory driven pathways. Hospitalized patients should receive thromboprophylaxis, but …

Thrombotic complications from COVID-19 are now well known and contribute to significant
morbidity and mortality. Different variants confer varying risks of thrombotic complications …